Since SET overexpression was always detected in combination with high p-PP2A and/or CIP2A (except 1 out of the 31 SET overexpression cases) and had no significant prognostic value in our cohort, we used a CPscore in which value 0 was assigned to absence of p-PP2A and CIP2A, value 1 to high p-PP2A or CIP2A overexpression, and value 2 to those breast cancer cases with high p-PP2A and CIP2A overexpression. The gene discussed is PTPA; the disease is breast carcinoma.